The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
The state-of-the-art facility is expected to be commissioned over the next three years
The move strengthens GBL’s clinical-stage presence in the United States
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Subscribe To Our Newsletter & Stay Updated
